A Phase II Study of MGCD0103 (MG-0103) Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

Trial Profile

A Phase II Study of MGCD0103 (MG-0103) Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2015

At a glance

  • Drugs Mocetinostat (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Therapeutic Use
  • Sponsors MethylGene
  • Most Recent Events

    • 03 Jun 2013 Data were presented at the 2013 ASCO Annual Meeting, according to a MethylGene media release.
    • 01 Feb 2012 Actual patient number (74) added as reported by ClinicalTrials.gov.
    • 01 Feb 2012 Actual end date (January 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top